- 专利标题： Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
-
申请号： US15511973申请日： 2015-09-17
-
公开(公告)号： US10577417B2公开(公告)日： 2020-03-03
- 发明人: Gregory Beatty , Boris Engels , Neeraja Idamakanti , Carl H. June , Andreas Loew , Michael C. Milone , Huijuan Song , Enxiu Wang , Qilong Wu
- 申请人： Novartis AG , The Trustees of the University of Pennsylvania
- 申请人地址： CH Basel US PA Philadelphia
- 专利权人： Novartis AG,The Trustees of the University of Pennsylvania
- 当前专利权人： Novartis AG,The Trustees of the University of Pennsylvania
- 当前专利权人地址： CH Basel US PA Philadelphia
- 代理机构： Lando & Anastasi, LLP
- 优先权： WOPCT/CN2014/086694 20140917; WOPCT/CN2014/090578 20141107
- 国际申请： PCT/US2015/050715 WO 20150917
- 国际公布： WO2016/044605 WO 20160324
- 主分类号： A61K35/17
- IPC分类号： A61K35/17 ; C07K14/705 ; C07K16/28 ; C07K16/30 ; C07K14/725 ; C07K14/74 ; C12N5/0783
摘要：
The present invention provides compositions and methods for regulating the specificity and activity of immune effector cells for use in immunotherapy. In one embodiment, the invention provides a type of chimeric antigen receptor (CAR) wherein the CAR is termed a “NKR-CAR” which is a CAR design comprising a component of a receptor naturally found on natural killer (NK) cells. In one embodiment, the NK receptor includes but is not limited to a naturally occurring activating and inhibitory receptor of NK cells known as a killer cell immunoglobulin-like receptor (KIR).
公开/授权文献
信息查询
IPC分类:
